13.01.2025 12:49:14
|
Johnson & Johnson To Buy Intra-Cellular Therapies For $132.00/shr In $14.6 Bln All-cash Deal
(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of biopharmaceutical company Intra-Cellular Therapies for $132.00 per share in cash for a total equity value of approximately $14.6 billion.
With this agreement, Johnson & Johnson adds Intra-Cellular Therapies' CAPLYTA (lumateperone), a once-daily oral therapy approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate.
The acquisition also includes ITI-1284, a promising Phase 2 compound being studied in generalized anxiety disorder (GAD) and Alzheimer's disease-related psychosis and agitation, as well as a clinical-stage pipeline that further complements and strengthens Johnson & Johnson's current areas of focus.
Johnson & Johnson expects to fund the transaction through a combination of cash on hand and debt. The closing of the transaction is expected to occur later this year subject to applicable regulatory approvals, approval by Intra-Cellular Therapies' stockholders and other customary closing conditions for a transaction of this type.
Following completion of the transaction, Intra-Cellular Therapies' common stock will no longer be listed for trading on the Nasdaq Global Select Market.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
05.03.25 |
Zuversicht in New York: Dow Jones am Nachmittag freundlich (finanzen.at) | |
05.03.25 |
Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel Gewinn hätte ein Investment in Johnson Johnson von vor 10 Jahren eingebracht (finanzen.at) | |
04.03.25 |
Minuszeichen in New York: Dow Jones zum Start des Dienstagshandels im Minus (finanzen.at) | |
03.03.25 |
Verluste in New York: Dow Jones fällt zum Ende des Montagshandels zurück (finanzen.at) | |
03.03.25 |
Schwacher Handel in New York: Dow Jones sackt am Montagnachmittag ab (finanzen.at) | |
03.03.25 |
Schwacher Handel in New York: Dow Jones verliert (finanzen.at) | |
27.02.25 |
Freundlicher Handel in New York: Dow Jones am Donnerstagmittag mit Zuschlägen (finanzen.at) | |
27.02.25 |
Handel in New York: Dow Jones startet im Plus (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Intra-Cellular Therapies Inc | 120,00 | -0,83% |
|
Johnson & Johnson | 152,18 | -0,37% |
|